Among renal cell carcinoma patients, high pre-treatment sPD-L1 correlated with shorter OS after treatment with (1) surgery, (2) surgery and first-line treatment with sunitinib, or (3) surgery and second-line treatment with axitinib [58]. The gene discussed is HOXD13; the disease is renal cell carcinoma.